Difference between revisions of "Team:NCTU Formosa"

Line 204: Line 204:
 
 
 
           <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" height=250px>  
 
           <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" height=250px>  
      <div class="photocontent1"><h2>Who are we</h2>
+
      <div class="photocontent1"><h2>Who we are</h2>
       NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
+
       NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
 
         devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to develop a brand     
 
         devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to develop a brand     
 
         new detection platform by using synthetic biology.</div>
 
         new detection platform by using synthetic biology.</div>

Revision as of 19:33, 18 September 2015

The only thing we can detect is everything.

Who we are

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to develop a brand new detection platform by using synthetic biology.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.